CASI Pharmaceuticals (NASDAQ:CASI) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Earnings and Valuation
This table compares CASI Pharmaceuticals and Cortexyme's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
CASI Pharmaceuticals | $4.13 million | 65.42 | $-46,030,000.00 | ($0.42) | -5.19 |
Cortexyme | N/A | N/A | $-36,980,000.00 | ($1.94) | -18.75 |
Cortexyme has lower revenue, but higher earnings than CASI Pharmaceuticals. Cortexyme is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for CASI Pharmaceuticals and Cortexyme, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
CASI Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Cortexyme | 2 | 1 | 4 | 0 | 2.29 |
CASI Pharmaceuticals currently has a consensus price target of $4.25, suggesting a potential upside of 94.95%. Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than Cortexyme.
Insider and Institutional Ownership
32.0% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 24.8% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares CASI Pharmaceuticals and Cortexyme's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
CASI Pharmaceuticals | -402.87% | -60.96% | -42.48% |
Cortexyme | N/A | -37.78% | -35.24% |
Volatility and Risk
CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
Summary
Cortexyme beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.